EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Rabia Shahswar, Razif Gabdoulline, Katja Krueger, Martin Wichmann, Katharina S Götze, Krischan Braitsch, Manja Meggendorfer, Laura Schmalbrock, Lars Bullinger, Franziska Modemann, Walter Fiedler, Juergen Krauter und 10 weitere

Leukemia · 2025-03 · 39 (3) · 614-622

DOI: 10.1038/s41375-024-02501-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Leukemia, online erschienen am 08.01.2025. Verfasst von Rabia Shahswar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (German Research Foundation), Deutsche Krebshilfe (German Cancer Aid).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded. Median overall survival (mOS) was 7.9 months. In multivariate analysis of the subgroup with molecular information ( n = 174), risk factors for inferior survival included the presence of extramedullary disease, HMA pretreatment and mutations in NF1 , PTPN11 , FLT3 , and TP53 , whereas mutated SF3B1 was identified as favorable risk factor. These risk factors were subsequently applied to construct an HR-weighted risk model that allocated patients to one of three risk groups with significantly different survival outcomes: favorable ( n = 46; mOS 21.4 months), intermediate ( n = 75; mOS 7.5 months), and adverse ( n = 53; mOS 4.6 months; p < 0.001). The model was validated in 189 AML patients treated with HMA/VEN in first line. This clinical-molecular, 3-tiered ven etoclax p rognostic r isk s core (VEN-PRS) for HMA/VEN treatment outcomes in R/R AML patients will support the selection of appropriate treatment options in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmNeoplasm Recurrence, LocalHumansMaleFemaleSulfonamidesBridged Bicyclo Compounds, HeterocyclicAgedMiddle AgedPrognosisRetrospective StudiesAged, 80 and overAdultSurvival RateRisk FactorsFollow-Up Studies

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Department of Medicine III, Technical University of Munich (TUM) School of Medicine and Health, Munich, Germany.
  • Bavarian Center for Cancer Research (BZKF), Erlangen, Germany.
  • MLL, Munich Leukemia Laboratory, Munich, Germany.
  • Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Oncology, Hematology and Bone Marrow Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft (German Research Foundation)
  • Deutsche Krebshilfe (German Cancer Aid)

Zitieren

APA

Shahswar, R., Gabdoulline, R., Krueger, K., Wichmann, M., Götze, K. S., Braitsch, K., Meggendorfer, M., Schmalbrock, L., Bullinger, L., Modemann, F., Fiedler, W., Krauter, J., Kaun, S., Rotermund, S., Voß, A., Behrens, Y. L., Bergmann, A. K., Koller, E., Beutel, G., …, & Heuser, M. (2025). A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia, 39(3), 614-622. https://doi.org/10.1038/s41375-024-02501-6

Vancouver

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, et al. A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39(3):614-622. doi:10.1038/s41375-024-02501-6

BibTeX
@article{Shahswar2025,
  author = {Shahswar, Rabia and Gabdoulline, Razif and Krueger, Katja and Wichmann, Martin and Götze, Katharina S and Braitsch, Krischan and Meggendorfer, Manja and Schmalbrock, Laura and Bullinger, Lars and Modemann, Franziska and Fiedler, Walter and Krauter, Juergen and Kaun, Stephan and Rotermund, Susanne and Voß, Andreas and Behrens, Yvonne Lisa and Bergmann, Anke Katharina and Koller, Elisabeth and Beutel, Gernot and Thol, Felicitas and Heidel, Florian and Heuser, Michael},
  title = {A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents},
  journal = {Leukemia},
  year = {2025},
  volume = {39},
  number = {3},
  pages = {614--622},
  doi = {10.1038/s41375-024-02501-6}
}
Kostenlos starten →